Andrea N. Loes

This study compares neutralizing antibody titers from egg-derived and recombinant protein influenza vaccines against diverse H1N1 strains, finding that egg-derived vaccines induce less boost against a new clade with specific antigenic mutations.

A sequencing-based neutralization assay across 78 H3N2 HA strains and 150 sera shows strain growth in 2023 tracks the fraction of sera with low titers, but not pooled-serum titers.

Sequencing-based neutralization of 91 H3N2 and H1N1 hemagglutinins against 302 human sera (27,409 titers) shows reduced titers to H3N2 subclade K and H1N1 D.3.1.1.

The paper measures how mutations in influenza HA affect function, stability, and antibody neutralization, showing epistasis enables antigenic change but cannot overcome pleiotropic costs that restrict evolutionary trajectories.

The paper quantifies neutralizing antibody responses to influenza strains using sera collected in 2024-2025 to inform vaccine-strain selection for 2025.

This study develops a high-throughput sequencing-based neutralization assay to measure antibody titers against multiple influenza strains and finds that vaccination effects vary by individual and prior vaccination history.